INTRODUCTION
Primary open-angle glaucoma (POAG) is a group of progressive optic neuropathies characterized by a slow and progressive degeneration of retinal ganglion cells (RGCs) and their axons, resulting in a distinct appearance of the optic disc and a concomitant pattern of vision loss (Zhang et al., 2012) . POAG is the most frequent type of glaucoma in the Western world, one of the world's leading causes of blindness, and the leading cause of blindness among African Americans (Weinreb et al., 2014) . Intraocular pressure (IOP) and age are the leading risk factors for both the development and the progression of POAG.
Recent genome-wide association studies have indicated that the SIX1-SIX6 and p16INK4a loci are among the strongest risk genes associated with POAG (Burdon et al., 2011; Osman et al., 2012; Wiggs et al., 2012) . SIX6 is a member of the homeodomain transcription factor family that has been shown to be required for proper eye development (Anderson et al., 2012) . Although several common variants have been identified within this locus, the newly described SIX6 risk variant SIX6-rs33912345 (His141Asn) is strongly associated with POAG (Carnes et al., 2014; Iglesias et al., 2014; Osman et al., 2012) , raising an intriguing question about the role of SIX6 in adult retina and in the pathology of POAG.
Expression of p16INK4a (cyclin-dependent kinase inhibitor 2A, isoform INK4a) is an indicator of irreversible growth arrest (senescence) in cultured cells and tissues (Campisi, 2013; Krishnamurthy et al., 2004; Naylor et al., 2013) . Senescent cells have been implicated in many age-associated degenerative phenotypes, often through secreted proteins, which are components of senescence-associated secretory phenotype (SASP) (Campisi, 2013) . Interestingly, it has been reported that selective elimination of p16Ink4a-positive senescent cells can prevent or delay age-related deterioration of mouse tissue (Baker et al., 2011) . p16Ink4a expression was found to be significantly elevated in a rat model of glaucoma (Burdon et al., 2011) , suggesting a role for p16-dependent pathway in the progression of the disease.
Here, using a combination of genetic association and functional studies, we show that SIX6 risk variant increases p16INK4a expression and leads to RGC senescence in cell culture, animal models, and human glaucoma retinas. This study provides insights into the mechanism of RGC death in glaucoma and suggests potential avenues for therapeutic intervention in glaucoma patients.
RESULTS
Association of SIX6-rs33912345 with Risk for POAG We performed genetic association studies and identified one missense variant of SIX6, rs33912345 (Genbank: NM_007374. 2, c.421C > A; Genbank: NP_031400.2, p.His141Asn), to be strongly associated with POAG. To further investigate the genetic association between SIX6-rs33912345 and POAG in the Caucasian population, rs33912345 (C/A) in the SIX6 gene was genotyped using a single-nucleotide primer extension assay in 1,130 POAG patients and 4,036 controls. The C risk allele frequency of rs33912345 in SIX6 was significantly higher in POAG patients (0.46) than in controls (0.38) (allelic p = 4.49 3 10 À12 , odds ratio [OR] 1.39, 95% CI 1.27-1.53) ( Figure 1A ). We proceeded to perform a replication study using a Mexican cohort with POAG and found a significant association (p = 0.011) (Table  S1) . We then performed meta-analysis using these two cohorts and another cohort reported in the literature (Carnes et al., 2014) . Together, the combined results indicate a significant association (allelic p = 4.84 3 10 À16 ) (Table S1 ).
The human risk allele His141 in SIX6 is conserved across species ( Figure 1B) , and amino acid 141 is located in the homeodomain of the SIX6 protein. Three-dimensional modeling indicated that this residue is positioned outside of the DNA-binding surface and thus is predicted to have no impact on DNA binding (Figure 1C) but could rather influence the ability of SIX6 to interact with other transcription factors and co-factors. To assess both SIX6 variants in vivo for their efficiency of binding to DNA regulatory elements, we first tested the specificity of our SIX6 antibody by chromatin immunoprecipitation (ChIP) assay on chromatins isolated from wild-type (WT) and Six6 knockout (KO) retinas. We observed that SIX6 protein could efficiently bind to the p27 regulatory element ( Figure S1A ), previously reported to be directly recognized by Six6 (Li et al., 2002) . Using the same approach, we observed that both the His141 and Asn141 variants of the SIX6 protein can bind the p27 regulatory element in patient-derived lymphoblastoid cells with similar efficiency (Figure 1D) . Additionally, we overexpressed HA-tagged versions of SIX6 in HEK293T cells and tested their ability to bind to the p27 regulatory element. ChIP experiments with antibodies specific to SIX6 protein or to the HA tag demonstrated that both forms of the SIX6 (His141 and Asn141) bind efficiently to the p27 regulatory region (Figures S1B and S1C). We therefore concluded that the presence of neither variant of residue 141 alters SIX6 binding efficiency to this known DNA-regulatory element, confirming our protein modeling prediction.
Joint Effect of SIX6 and p16INK4a on POAG Risk Because SIX6 and p16INK4a (Genbank: NM_000077) are the two genes showing the strongest genetic association with POAG risk, we investigated the joint effect of SIX6-rs33912345 and p16INK4a-rs3731239 on POAG risk using a logistic regression model and calculated ORs. A global two-locus (9 0 2) contingency table, enumerating all nine two-locus genotype combinations, was constructed. Compared with that of a baseline of non-risk alleles SIX6-rs33912345 AA and p16INK4a-rs3731239 GG, the OR of the risk alleles SIX6-rs33912345 CC and p16INK4a-rs3731239 AA was 2.73 (p < 0.05, 95% CI 1.63-4.62) (Figure 2A ), suggesting their joint effect on POAG risk.
To investigate the correlation between SIX6-rs33912345 and p16INK4-rs3731239 genotypes and the expression of SIX6 and p16INK4a, mRNA levels of both genes were measured in patient-derived human lymphoblastoid cells using reverse transcription followed by quantitative PCR (RT-qPCR). We detected higher SIX6 levels (1.4-fold) in cell lines carrying the SIX6 risk allele. In addition, the expression of p16INK4a mRNA was 2.3-fold higher in cells with risk genotype compared with the cells with protective genotype ( Figure 2B ). We further measured the levels of p16INK4a mRNA in retinas from healthy and glaucoma patients and observed significantly elevated expression in glaucoma eyes ( Figure S2B ). To investigate whether the elevated expression of p16INK4a correlated with increased cellular senescence, a senescence-associated b-galactosidase (SA-bgal) assay was performed on healthy and glaucoma human retinas. Consistently, retinas from glaucoma patients exhibited elevated senescence, as indicated by a significantly larger number of blue-positive cells in the ganglion cell layer (GCL) ( Figures  2C, 2D , and S2A).
Transcriptional Regulation of p16INK4a by SIX6
To investigate whether SIX6 is involved in transcriptional regulation of p16INK4a, we transiently expressed SIX6-His141 or SIX6-Asn141 variants in human fetal retinal progenitor cells (fRPCs) and quantified p16INK4a mRNA levels using RT-qPCR. Significantly higher expression of p16INK4a mRNA was observed in SIX6-His141-transfected cells ( Figure 3A ). Similar trends were observed when SIX6-His141 and SIX6-Asn141 were expressed at similar levels in HEK293T cells ( Figures 3B and 3C ), which suggests that the effect of the variation in SIX6 is not cell type specific. To test whether both HA-tagged SIX6 protein variants can bind directly to p16INK4a promoter, we performed ChIP assays using anti-SIX6 and anti-HA antibodies. We observed that both protein variants bind to p16INK4a promoter with similar efficiency ( Figure 3D and not shown). Taken together, these data suggest that SIX6 can act as a direct activator of p16INK4a gene and that the SIX6-His141 variant has more potential to activate p16INK4a expression.
Given that elevated expression of p16INK4a is a hallmark of cellular senescence (Campisi, 2013; Naylor et al., 2013) , we tested whether transient overexpression of either variant of SIX6 (SIX6-His141 and SIX6-Asn141) could induce senescence in fRPCs. Interestingly, merely 24 hr post-transfection, fRPCs expressing SIX6-His141 variant underwent senescence twice as readily as those under control conditions or those transfected with SIX6-Asn141 variant, as assessed by a SA-bgal assay and by upregulation of interleukin-6 (IL6), a secretory marker of senescence (Figures 3E, 3F, and S3) . Taken together, these data indicate that SIX6-His141 risk variant increased senescence in fRPCs by direct induction of p16INK4a expression.
Upregulation of Six6 and p16Ink4a in a Mouse Model of Acute Glaucoma Experimental ocular hypertension mouse models have been used extensively to study the relationship between IOP and the mechanism of glaucomatous optic neuropathy (Gross et al., 2003) . To investigate the association of glaucoma in the context of SIX6-His risk variant and p16INK4a expression, we used a mouse glaucoma model in which the IOP is increased acutely. First, we analyzed the sequence of mouse Six6 gene and noticed that mouse genome encodes only the Six6-His variant (Figure 1B) . Western blot analysis confirmed that SIX6 was expressed in the adult retina at levels comparable with those observed in the embryonic stages ( Figure 4A ). When both Six6 and p16Ink4a mRNA levels were measured 5 days after IOP elevation, both Six6 and p16Ink4a mRNA expression levels were significantly higher in retinas from IOP-treated eyes compared with those from control eyes ( Figure 4B ). We also noted increased expression of p15Cdkn2b and p19Arf upon IOP elevation (Figures S4A and S4B) .
Because SIX6 binds to p16INK4a promoter upon engineered expression in cell culture ( Figure 3D ), we asked if SIX6 could also bind to this promoter in adult mouse retina in vivo. To test this, we compared ChIP efficiency in chromatins isolated from WT and Six6 KO retinas. We found that detectable signal could only be observed in WT retinas, not in Six6 À/À retinas ( Figure S4C ).
Further, we investigated whether SIX6 binding to p16Ink4a promoter in the retina was altered by IOP elevation. We performed a ChIP-qPCR assay in chromatins isolated from IOP-elevated and control retinas and observed that binding of SIX6 to the p16Ink4a promoter was significantly elevated upon increased IOP ( Figure 4C ). This phenomenon correlated with elevated recruitment of histone acetyltransferase p300, a known co-activator of p16Ink4a expression ( Figure 4D ) (Wang et al., 2008) , and increased pan-acetylation of histone H3, a modification that is associated with active regulatory elements ( Figure 4E ) (Strahl and Allis, 2000) . Importantly, there was no recruitment of SIX6 to p19Arf or p15Cdkn2b promoters upon IOP elevation ( Figure S4D ), suggesting that the effect of SIX6 on p16Ink4a is gene specific. We then used a SA-bgal assay to test if the cells in the treated retinas had undergone senescence. As expected, in five of five mice tested, we observed a dramatic accumulation of senescent cells in the IOP-treated retinas, compared with only a few senescent cells observed in untreated retinas ( Figures 4F and S4E ). We further investigated whether it was the RGCs that underwent senescence in IOP-treated retinas. As expected, images of the retinal cross-sections showed that most of the senescent cells were localized in the GCL ( Figure 5A ). We performed immunohistochemistry using an anti-BRN3a antibody (an RGC marker) on IOP-treated and non-treated flat-mount retinas and detected that most of the b-galactosidase-positive cells were also BRN3a positive ( Figure 5B ). We further confirmed these findings by comparing the b-gal staining pattern in Thy1-CFP transgenic mice, in which the RGCs are specifically marked by CFP fluorescence (Figures 5C and S5A) (Lindsey et al., 2013) .
We next investigated the effects of engineered expression of SIX6 variants on the expression of p16Ink4a and SASP marker, IL6, in cultured RGCs. RGCs from rat retina were isolated by immunopanning using anti-Thy-1 antibody (Winzeler and Wang, 2013) (Figure 5D ). The efficacy of this procedure was verified by cell morphology and Brn3a expression levels in isolated RGCs compared with whole retina cells ( Figures S5D and  S5E ). Significantly, we observed increased expression of p16Ink4a and IL6 only in the RGCs in which we introduced the His variant of SIX6 ( Figures 5E, S5F , and S5G). Consistently, there were remarkably more IL6-positive RGCs in the IOPtreated retinas than in controls ( Figures S5B and S5C) . Taken together, these data suggest that RGCs are the primary cells affected in this glaucoma model.
Lack of Either Six6 or p16Ink4a Protects against RGC Death in Glaucoma
The homozygous Six6 KO adult retinas display numerous abnormalities (Clark et al., 2013) , especially in the RGC layer. Therefore, we decided to use heterozygous mice to test the role of SIX6 in induced senescence and in the regulation of p16Ink4a expression. As before, acute IOP elevation was applied, and retinas were collected and assayed 5 days after IOP. In contrast to the WT littermates, reduced Six6 expression was accompanied by decreased p16Ink4a expression upon IOP elevation in Six6 +/À retinas ( Figures 6A and 6B ). Interestingly, in Six6
mice, no b-gal-positive cells could be observed ( Figures 6C  and S6A ), suggesting that haploinsufficiency of SIX6 was sufficiently protective against senescence in RGCs. Together, these results suggest a model in which increased p16Ink4a expression is a major cause of cellular senescence in glaucoma. We then tested whether the lack of p16Ink4a expression in p16Ink4a À/À mice could prevent RGC death in our acute glaucoma model. Indeed, consistent with the above data, absence of p16Ink4a expression protected against RGC death ( Figure 6D ). Because P53 has been reported to play an important role in senescence (Campisi, 2013) , we asked whether the lack of P53 can prevent RGC death caused by IOP elevation. To test this, we compared the numbers of RGCs in IOP-treated mouse retinas from p53 À/À mice to IOP-treated WT mice. We found that the lack of p53 significantly attenuated RGC death upon IOP compared with WT mice ( Figure 6E ). We also observed a Figure S4 .
genetic association of a missense variant in P53 (rs1042522) (Genbank: NM_000546.5, c.215C > G; Genbank: NP_000537. 3, p.Pro72Arg) with POAG, consistent with its role in glaucoma pathogenesis ( Figure S6B ). Taken together, these findings lead us to propose a model ( Figure 6F ) in which IOP elevation causes the upregulation of p16INK4a through increased expression of SIX6 (in particular the His variant) and its binding to the p16INK4a promoter. Increased p16INK4a expression causes RGCs to enter cellular senescence. Prolonged senescence can cause increased RGC death and consequent blindness.
DISCUSSION
Glaucoma is the leading cause of blindness, affecting tens of millions of people worldwide. Despite its prevalence, its etiology and pathogenesis are poorly understood, and treatment is limited to lowering IOP. Despite aggressive IOP-lowering therapies, most patients have progressive loss of visual function, and some eventually become legally blind. The relationship of raised IOP and RGC death is poorly understood. Cellular senescence is a state of irreversible growth arrest. When senescent cells accumulate in the tissue, their impaired function can result in a predisposition to disease development and/or progression (Baker et al., 2011; Burton, 2009; Campisi, 2013) . In the present study, we show that SIX6 directly regulates expression of p16INK4a, an indicator of cell senescence and aging. Furthermore, we show that upon acute IOP elevation, p16INK4a expression is upregulated, which, in turn, can be a cause of RGC death. Therefore p16INK4a upregulation appears to be a downstream integrator of diverse signals such as inherited genetic risk, age, and other factors, such as raised IOP. Our hypothesis can help explain how IOP, the most common risk factor, can cause glaucoma. Moreover, it provides a molecular link between genetic susceptibility and other factors to the pathogenesis of glaucoma.
Our study suggests that cellular senescence plays a critical role in the pathogenesis of glaucoma. Consistent with this notion, we show that another key player in cellular senescence, P53 (Campisi, 2013) , also contributes to RGC death, as evidenced by protection of RGC from IOP induced damage in mice lacking p53. Additionally, we provide data showing increased expression of secretory molecules, components of SASP, upon IOP-induced retinal damage. Moreover, we recently demonstrated that induction of interleukin-1 (IL1) is an early response to IOP-induced RGC damage (Chi et al., 2014) . Induction of IL1, in turn, is known to cause activation of NF-kB-dependent senescence-associated expression of IL6 and interleukin-8 (Orjalo et al., 2009) . Our data thus suggest that the senescenceassociated cytokine network is activated in IOP-treated retinas.
p16INK4a is a cyclin-dependent kinase inhibitor and a potent negative regulator of cell-cycle progression. Consequently, upregulated p16INK4a expression and senescence phenotype, as measured by SA-bgal assay and SASP, usually indicate the irreversible cell-cycle arrest (Campisi, 2013) . In our study, however, elevated p16INK4a expression and senescence were observed in RGCs (post-mitotic neurons), which are believed not to be replication competent. Therefore, one possibility is that RGCs may contain a replication-competent, stem cell-like population; alternatively, p16INK4a may play a previously unrecognized role in these post-mitotic cells.
Although the primary focus of the present study was on the role of p16INK4a on RGC death, our data do not exclude a potential role for other genes located in the 9p21 locus in the pathology of glaucoma. For example, p14ARF may contribute to glaucoma pathogenesis independently by influencing eye vasculature development (McKeller et al., 2002) . Further studies are required to elucidate role of p14ARF and p15CDKN2B in the pathogenesis of glaucoma.
SIX6 is a member of the SIX/Sine oculis family of homeobox transcription factors involved in the development of retina (Gal- , 1999) . It has been shown to directly regulate the expression of cyclin-dependent kinase inhibitor genes (Li et al., 2002) as well as GnRH (Larder et al., 2011) during mouse development. Although the role of SIX6 during retina development is being investigated by a number of laboratories, there are very few reports exploring its molecular role in adult retina or in glaucoma pathogenesis. Several SIX6 mutations and SNPs have been shown to correlate with developmental eye defects in human (Aldahmesh et al., 2013; Gallardo et al., 1999 Gallardo et al., , 2004 . Additionally, several SNPs have been associated with an increased risk for glaucoma (Carnes et al., 2014; Iglesias et al., 2014) . The effects of SIX6 variants had always been assessed after late identification of the disease, and this approach does not allow for correct dissociation of developmental defects from the genetic components that cause the disease.
The SIX6 variant referred to as ''risk'' (histidine-encoding SIX6-His) is actually evolutionary conserved across the phyla. The Asn variant (the protective allele for glaucoma) is detected only in the human branch; however, it is unknown why it would be advantageous for humans to have a protective variant. Several groups performed rescue experiments by overexpressing human His variant in zebrafish and found that it did not rescue eye defects induced by the removal of endogenous SIX6 proteins. Interestingly, both zSix6a and zSix6b carry the His amino acid at the orthologous position (Carnes et al., 2014; Iglesias et al., 2014) . These results suggest that the inability to rescue eye phenotypes by human His version of SIX6 is likely the result of species-specific differences in other residues and not the sole effect of His/ Asn variant.
Taken together, our study shows that SIX6 His variant increases p16INK4a expression upon increased IOP, which in turn causes RGCs to enter into a senescent state and which may lead to increased RGC death in glaucoma. Our study provides important insights into the pathogenesis of glaucoma and suggests future therapeutic strategies based on targeted inhibition of p16INK4a-induced cell senescence to prevent and treat glaucoma.
EXPERIMENTAL PROCEDURES Subjects and Test Procedure
This study was approved by the institutional review boards (IRBs) of the University of California, San Diego, the University of Southern California, and West China Hospital. All participants signed informed-consent statements prior to participation. Blood was drawn from a vein in the patient's arm into blood collection tubes containing the anticoagulant acid citrate dextrose. Genomic DNA was extracted from peripheral blood leukocytes with the Qiagen kit, according to the manufacturer's instructions. For the initial cohort, 1,130 POAG patients and 4,036 controls were enrolled in this study. All participants were of European descent. For the Mexican cohort, 105 POAG patients and 188 controls were enrolled in this study.
Clinical Definitions
Clinical assessment was performed using previously described methods (Wiggs et al., 2012) . POAG patients were defined as individuals for whom reliable visual field (VF) tests showed characteristic VF defects consistent with glaucomatous optic neuropathy. Individuals were classified as affected if the VF defects were reproduced on a subsequent test or if a single qualifying VF was accompanied by a cup-disc ratio (CDR) of 0.7 or more in at least one eye. The examination of the ocular anterior segment did not show signs of secondary causes for elevated IOP, such as exfoliation syndrome or pigment dispersion syndrome, and the filtration structures were deemed to be open on the basis of clinical measures. Controls had normal optic nerves (CDRs % 0.6) and normal IOP (Wiggs et al., 2012) .
Genotyping and Statistical Analysis
Genomic DNA was extracted from peripheral blood leukocytes with the Qiagen kit, according to the manufacturer's instructions. rs33912345 (C/A) in SIX6, rs3731239 (A/G) in p16INK4a, and rs1042522 (C/G) in P53 were genotyped using single-nucleotide primer extension assay (ABI Prism SNaPShot Multiplex Kit; Applied Biosystems) on an ABI 3130xl genetic analyzer, as previously described (Yang et al., 2006) . The primers used for genotyping are listed in Table S2 . SNP genotyping results were screened for deviation from Hardy-Weinberg equilibrium using chi-square tests. Allele association was calculated with a chi-square test performed using the program PLINK (Purcell et al., 2007) (RRID: nlx_154200; http://pngu.mgh.harvard.edu/purcell/plink/). Asymptomatic p values were also generated for this test.
Joint Effects of SIX6-rs33912345 and p16INK4a-rs3731239 Joint effects of SIX6-rs33912345 (C/A) and p16INK4a-rs3731239 (A/G) were calculated by a logistic regression model (Chen et al., 2010 (Chen et al., , 2011 . A global two-locus (9 0 2) contingency table, enumerating all nine two-locus genotype combinations, was constructed. ORs and 95% CIs, comparing each genotypic combination with the baseline of homozygosity for the common allele at both loci, were calculated, according to the previously described methods (Chen et al., 2010 (Chen et al., , 2011 .
Three-Dimensional Modeling of the SIX6 H141N Variation
We performed a computer modeling analysis to investigate the effects of the SIX6 His141Asn variation on the 3D structure and function of SIX6 with the ICM software (Cardozo et al., 1995) . The SIX6 transcription factor has never been crystallized for X-ray analysis or studied by nuclear magnetic resonance (NMR). To build a structural model of the DNA-binding domain around the H141N variation, we searched the Protein Data Bank for homologous transcription factors. The search identified the following entries with fragments of related transcription factors: 2DMU, 1QRY, 1VND, 1YRN, 2LKX, and two solved by crystallography or NMR. Then we attempted a structural superposition of the identified domains. All had a structurally (topologically) similar DNA-binding motif, covering the area from residues around 134-189. The structural homology model of SIX6 was built for residues from 134-189 with the ICM software (Cardozo et al., 1995) by threading the SIX6 sequence onto the consensus structure.
Lymphoblastoid Cell Lines Culture
The human lymphoblastoid cell lines were generated by the method ''General Protocol for the Immortalization of Human B-Lymphocytes Using EBV'' (http://www.unclineberger.org/tissueculture/protocols/b-lymphocytesprotocol). Four lymphoblastoid cell lines with the genotypes of SIX6 rs33912345-CC and another four with the genotypes of SIX6 rs33912345-AA were used. The cells were cultured in RPMI-1640 base medium (61870127; Invitrogen) supplemented with 20% fetal bovine serum and 1 3 penicillin-streptomycin (P0781; Sigma). RNA was extracted and the total mRNA levels of SIX6 and p16INK4a were measured by RT-qPCR.
Acute IOP Mouse Model
Unilateral elevation of IOP in 1-month-old C57BL/6J, p16Ink4a
, Thy1-CFP (Lindsey et al., 2013) , Six6 +/À (Larder et al., 2011) , and p53 À/À (129-Trp53tm1Tyj/J; The Jackson Laboratory) mice was achieved through instilling the anterior chamber with saline solution and maintained at an elevated pressure of 90 mm Hg. The p16Ink4a À/À line was engineered to remove the common exon of E2 and E3; therefore, the line is a null allele for both p16Ink4a and p19Arf genes (Serrano et al., 1996) . IOP was measured by a tonometer. All procedures were conducted with the approval and under the supervision of the Institutional Animal Care Committee at the University of California, San Diego, and adherence to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. C57BL/6J male mice were purchased from The Jackson Laboratory. To elevate IOP experimentally, animals were first anesthetized with a weight-based intraperitoneal injection of ketamine (80 mg/kg) and xylazine (16 mg/kg). Additional anesthesia was provided via the same route at 45 min intervals. Corneal anesthesia was achieved with a single drop of 0.5% proparacaine hydrochloride (Alcon Laboratories). A drop of 0.5% proparacaine hydrochloride and 0.5% tropicamide (Alcon Laboratories) was then applied to the right eye. Body temperature was maintained between 37 C and 38 C, with a water-heat pad (TP500T/Pump; Gaymar Industries). A 30-gauge needle was used to puncture the mid-peripheral cornea of the right eye; the anterior chambers were cannulated with sterile physiologic saline (balanced salt solution; Alcon Laboratories), and IOP was manometrically controlled by adjusting the saline height. IOP was monitored with an indentation tonometer (Tonolab; Icare) and maintained at 90 mm Hg pressure for 1 hr. Assessment of the senescence of RGCs was made in retinal flat mounts harvested 5 days after experiments. In brief, mice were euthanized with CO 2 , and eyeballs were dissected and fixed in ice-cold phosphate-buffered 4% paraformaldehyde (pH 7.4) for 30 min, followed by flat mounting of the retinas.
SA-bgal Assay to Test Senescence on Retinas from Human and IOP Mouse Eyes
Senescence assays were performed using the Senescence b-Galactosidase Staining Kit (Cell Signaling) according to the manufacturer's protocol. For double staining, senescence assays were followed by anti-GFP antibody staining to reveal full fluorescence of Thy1-CFP retinas.
RNA Extraction and Real-Time PCR Total RNA extraction from mouse tissues or human lymphoblastoid cells, cDNA synthesis, and RT-qPCR experiments were performed as previously described (Luo et al., 2013) . Assays were performed in triplicate. Relative mRNA levels were calculated by normalizing results using GAPDH. The primers used for RT-qPCR are listed in Table S2 . The differences in quantitative PCR data were analyzed with an independent two-sample t test.
Human fRPC Isolation and Expansion
All work with human material was performed with IRB approval. fRPCs were isolated from human fetal neural retina at 16 weeks gestational age, as previously described (Luo et al., 2014) . Whole neuroretina was separated from the retinal pigment epithelium layer, minced, and digested with collagenase I (Sigma-Aldrich). Cells and cell clusters were plated onto human fibronectin (Akron)-coated flasks (Nunclon Delta) in Ultraculture Media (Lonza), supplemented with 2 mM L-glutamine (Invitrogen), 10 ng/ml rhbFGF (Peprotech), and 20 ng/ml rhEGF (Peprotech) in a low-oxygen incubator (37 C, 3% O 2 , 5% CO 2 , 100% humidity). Cells were passaged at 80% confluency using TrypZean (Sigma-Aldrich), benzonase (EMD Chemicals), and Defined Trypsin Inhibitor (Invitrogen).
Immunopanning
The immunopanning procedure and RGC culture were performed according to the published detailed protocol (Winzeler and Wang, 2013) .
Plasmid Transfection into Human Embryonic Kidney 293 Cells and fRPCs
Overexpression was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's standard protocol. Empty or GFP-containing vector was used as a negative control. For ChIP and expression analysis experiments, cells were harvested 48 hr post-transfection. For senescence analysis in fRPCs, cells were collected after 24 hr.
ChIP
ChIP was performed as previously described (Skowronska-Krawczyk et al., 2004 , 2009 ). Briefly, cells or dissected retinas were fixed for 10 min with 1% formaldehyde; chromatin was isolated and sonicated to obtain fragments 300-700 bp in length. After adding antibodies, immunoprecipitation was carried out overnight, and protein/DNA complexes were pulled out using protein G-coated magnetic beads (Invitrogen). After 3 washes, DNA crosslinking was reversed. The DNA was then purified and subjected to qPCR. All experiments were repeated at least three times. The p values were calculated using Student's t tests. 
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